GAMA
RARE icon

Graticule Asia Macro Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Graticule Asia Macro Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-58,100
Closed -$5.6M – 191
2015
Q3 		$5.6M Buy
+58,100
New +$6.65M 0.65% 27

Other funds holding RARE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Graticule Asia Macro Advisors's RARE Position: Q4 2015 in Review

Graticule Asia Macro Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2015, closing a stake of 58,100 shares — an estimated $5.6M sold.

Graticule Asia Macro Advisors first reported a position in RARE in Q3 2015 and held it in 1 quarter. The position peaked at $5.6M in Q3 2015. 171 funds tracked by Wall St. Rank hold RARE as of Q4 2015.

  • Graticule Asia Macro Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q4 2015 after selling out during the quarter.
  • Graticule Asia Macro Advisors sold 58,100 Ultragenyx Pharmaceutical shares in Q4 2015, an estimated $5.6M.
  • Graticule Asia Macro Advisors first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and held it in 1 quarter.
  • Graticule Asia Macro Advisors's Ultragenyx Pharmaceutical position peaked at $5.6M in Q3 2015.
  • 171 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2015.

Based on Graticule Asia Macro Advisors's 13F filing for Q4 2015, filed 12 Feb 2016.